Up to 175% Return in 1–3 Years? Market Guru Picks Wockhardt and Jubilant Pharmova
Two pharmaceutical stocks—Wockhardt and Jubilant Pharmova—are back in the spotlight after market expert Anil Singhvi highlighted them as long-term ideas for investors willing to stay invested for one to three years. The bullish targets suggest potential returns ranging up to around 175%, depending on the stock, entry price and the target achieved.
However, these are market views and target prices, not guaranteed returns. Both companies have different business drivers, and investors should understand the opportunities and risks before treating a headline-making target as an investment decision.
Wockhardt was highlighted with multiple upside levels, while Jubilant Pharmova was also presented as a potential medium-term opportunity. The recommendations come at a time when pharmaceutical stocks are attracting renewed attention, driven by product launches, manufacturing expansion and changing earnings expectations.
Wockhardt: Why Is the Stock Attracting Attention?
Wockhardt has been one of the more volatile and closely watched pharma stocks in the Indian market. The company has attracted investor interest because of its efforts to strengthen its pharmaceutical business and the potential value of its product pipeline.
According to the recommendation highlighted by Zee Business, Wockhardt was among the two pharma stocks selected for a one-to-three-year investment horizon. The bullish case is based on the expectation that business developments and future execution could support further value creation.
The stock's market price has also moved sharply in recent sessions. On September 4, Wockhardt touched an intraday high of around ₹2,090, according to market data, after trading near ₹1,950 in the previous session. That means investors reading older recommendations should not assume that the original entry price is still available.
A Return to Profitability Is an Important Development
Wockhardt reported a consolidated net profit of ₹106 crore for the June 2026 quarter, compared with a net loss of ₹90 crore in the corresponding quarter a year earlier. Quarterly sales rose nearly 26% year-on-year to ₹929 crore.
For investors, the significance is not just one profitable quarter. The larger question is whether the company can maintain earnings growth and convert its product pipeline and business initiatives into sustainable cash flows.
That is what could ultimately determine whether the stock can justify significantly higher levels over the next one to three years.
What Could Drive Wockhardt Higher?
The main factors investors may want to track include:
Progress in its pharmaceutical and antibiotic pipeline
Regulatory approvals and commercial launches
Revenue growth from new products
Sustainability of profitability
Debt and balance-sheet developments
Regulatory or legal risks
Wockhardt's 52-week trading range has also been wide, illustrating the stock's volatility. Market data showed a 52-week high above ₹2,400 and a low near ₹1,087 during the period covered by recent data.
This means the potential upside comes with substantial risk. A promising drug pipeline can create value, but delays, regulatory issues or weaker-than-expected commercial performance can also affect investor sentiment.
Jubilant Pharmova: A Different Growth Story
Jubilant Pharmova's investment case is less dependent on a single catalyst. The company operates across multiple pharmaceutical-related businesses, with contract development and manufacturing among the areas investors are watching closely.
The stock was also included in Anil Singhvi's long-term pharma picks for a one-to-three-year horizon.
As of September 4, recent market data showed Jubilant Pharmova trading around the ₹900–₹925 range, although prices can change throughout the trading session.
Revenue Growth Needs to Translate Into Stronger Profits
The key investment question for Jubilant Pharmova is whether business growth can translate into consistent earnings expansion.
Recent market data showed that the company's latest quarterly revenue trend remained positive, while profitability trends have faced pressure. This makes future margin improvement an important factor for investors to monitor.
For a growing pharmaceutical business, expansion can initially require significant investment. New facilities, technology transfers, manufacturing capacity and regulatory compliance can increase costs before the full financial benefits become visible.
If utilisation improves and higher-value businesses scale successfully, margins could become an important catalyst. But that remains dependent on execution.
Where Does the “Up to 175% Return” Claim Come From?
The headline figure is based on the difference between the recommended entry price or CMP and the highest target discussed for the selected stocks.
Investors should be careful with such calculations.
For example, if a stock is recommended at ₹1,950 with a highest target of ₹5,000, the theoretical upside is calculated from those two levels. But if the stock has already moved significantly higher before an investor buys it, the potential return changes immediately.
That is why copying a recommendation after a sharp rally can be risky.
A target price represents an expectation or market view. It does not mean the stock will definitely reach that level within the stated period.
Wockhardt vs Jubilant Pharmova: What Investors Should Compare
| Factor | Wockhardt | Jubilant Pharmova |
|---|---|---|
| Main investment theme | Product pipeline and business turnaround | Pharmaceutical manufacturing and business expansion |
| Key opportunity | Successful product launches and sustained earnings | Revenue growth and improved profitability |
| Major catalyst | Regulatory and commercial progress | Capacity utilisation and margin expansion |
| Key risk | High volatility and execution uncertainty | Profitability and business execution |
| Investment horizon discussed | 1–3 years | 1–3 years |
The comparison shows why investors should avoid looking only at the percentage return potential.
A stock with a higher target is not automatically the better investment. Valuation, earnings quality, debt, cash flow, regulatory risks and the ability of management to execute are equally important.
What Should Investors Watch Next?
For Wockhardt, the next few quarterly results and updates around its pharmaceutical pipeline could be particularly important. Investors will want to see whether the improvement in profitability can continue and whether new products can generate meaningful revenue.
For Jubilant Pharmova, attention is likely to remain on revenue growth, operating margins and the performance of its key business segments.
Institutional ownership is another factor investors may monitor. Recent data showed mutual funds and foreign investors holding meaningful stakes in Jubilant Pharmova, although shareholding patterns can change from quarter to quarter.
For both stocks, investors should also watch:
Quarterly earnings
Regulatory announcements
New product approvals
Management guidance
Debt and cash-flow trends
Valuation after any sharp price rally
The Bottom Line
The bullish calls on Wockhardt and Jubilant Pharmova highlight the potential opportunities emerging in selected pharmaceutical businesses, but the headline claim of up to 175% returns should be treated as a market expectation—not a promise.
Wockhardt's recovery in profitability and its pharmaceutical pipeline could create significant upside if execution remains strong. Jubilant Pharmova offers a different opportunity, centred on business growth and the possibility of improving profitability over time.
For investors considering a one-to-three-year horizon, the most important step is to track business performance rather than becoming anchored to a particular target price. Strong earnings execution can support a higher valuation; disappointing results can quickly change the investment case.
Follow our blog for more stock market, business, pharmaceutical sector and investment updates.
This article is for informational and educational purposes only and should not be considered investment advice.